Progressive breast fibrosis caused by extreme radiosensitivity: Oncocytogenetic diagnosis and treatment by reconstructive flap surgery by Mészáros, Norbert et al.
Received: 27 March 2018 Revised: 27 June 2018 Accepted: 28 June 2018
DOI: 10.1002/cnr2.1126CA S E R E POR TProgressive breast fibrosis caused by extreme radiosensitivity:
Oncocytogenetic diagnosis and treatment by reconstructive
flap surgery
Norbert Mészáros1,2 | Gyöngyi Farkas3 | Gábor Székely3 | Zsuzsa S. Kocsis3 |
Péter B. Kelemen4 | János Fodor1 | Csaba Polgár1,2 | Zsolt Jurányi31Centre of Radiotherapy, National Institute of
Oncology, Budapest, Hungary
2Department of Oncology, Semmelweis
University, Faculty of Medicine, Budapest,
Hungary
3Department of Radiobiology and Diagnostic
Onco‐Cytogenetics, Centre of Radiotherapy,
National Institute of Oncology, Budapest,
Hungary
4Department of Breast and Sarcoma Surgery,
National Institute of Oncology, Budapest,
Hungary
Correspondence
Norbert Meszaros, Centre of Radiotherapy,
National Institute of Oncology, Rath Gyorgy u.
7‐9, Budapest H‐1122, Hungary.
Email: meszarosnorbert@oncol.huCancer Reports. 2019;2:e1126.
https://doi.org/10.1002/cnr2.1126Abstract
Background: Fibrosis, a proliferative response of fibrocytes after tissue injury, is a
common sequela of external radiotherapy and can vary greatly among patients even
in the absence of DNA repair syndromes, due to their different intrinsic radiosensitiv-
ity. Fibrosis is also a serious cosmetic problem for patients, and in some cases it can
also imply pain.
Case: Here, we report a case of a severe fibrosis 2 years after breast conserving
surgery and postoperative 3D conformal breast irradiation. Furthermore, our patient
had the suspicion of tumour recurrence. Our examinations were aimed at diagnosing
recurrence or the lack of recurrence and investigating whether the symptoms
occurred due to overdosing or extreme intrinsic radiosensitivity. Therefore, examining
the patients' radiosensitivity, a cytogenetic test was performed, which revealed the
patient's increased susceptibility to ionizing radiation, and therefore we rejected the
prospect of overdosage. As a solution for the fibrosis, mastectomy was effectuated,
and a latissimus dorsi musculocutaneous flap was used for reconstruction.
Conclusions: We suggest a multi‐disciplinary approach to manage fibrosis and pro-
pose cytogenetic markers to be used as predictors to identify patients who most likely
benefit from a certain therapeutic regimen in terms of reduction of therapy‐related
side effects.
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Breast conservation therapy is a preferable option for women with
early‐stage breast cancer. It consists of resection of the primary breast
tumour then followed by whole breast irradiation with a total dose of
45 to 50 Gy. The principal long‐term side effect of breast radiotherapy
is fibrosis, a serious cosmetic and psychological problem that might be
a painful condition for the patient. Besides fibrosis telangiectasis,
lymphoedema in the arm and breast oedema occur, and patients often
experience moderate or severe pain in the breast, arm, or shoulder.1,2wileyonlinelibrary.com/jouRadiotherapy of breast cancer can also induce late complications in
pulmonary and cardiac tissue leading to pulmonary apical fibrosis,3
pericardial disease, myocardial fibrosis, coronary artery disease, and
valvular lesions.4 This aspect of therapeutic intervention is especially
accentuated nowadays, when due to the early diagnosis and effective
treatments, mortality from breast cancer is decreasing; however,
reducing late toxicity is becoming increasingly important.
Fibrosis represents a proliferative response of the surviving
fibrocytes due to growth factors released after tissue injury caused
by ionizing radiation. Histological and immunological signs of© 2018 Wiley Periodicals, Inc.rnal/cnr2 1 of 6
2 of 6 MÉSZÁROS ET AL.radiation‐induced fibrosis include the presence of inflammatory infil-
trate, macrophages, fibroblasts, matrix proteins, collagen, and growth
factor beta 1 (transforming growth factor),1 which regulates epidermal
growth factor, fibroblast growth factor, tumour necrosis factor, and
interleukin‐1 production.5 While healing of a simple tissue injury might
seem a prospective process in time, fractionated radiation therapy
produces a series of repeated trauma for tissues. Therefore, during
the course of radiation therapy, many steps of the inflammatory
process have been repeated leading to a cumulative response.6 A
retrospective study proved that age and the presence of allergy
(which includes constant inflammation) were significantly associated
with susceptibility to breast fibrosis.7
Depending on the late responses of normal tissue, induration, tis-
sue hardening, and changes in shape and volume of the treated breast
might appear. Radiation fibrosis and telangiectasia might occur after
radiotherapy, but severe cases due to intrinsic sensitivity are rare. In
this article, we do not want to compare our case with syndromatic
cases such as seen in Ataxia telangiectesia, Fanconi anaemia,
Xeroderma pigmentosum patients. In those cases, one already proven
gene deficiency causes several symptoms and radiosensitivity also. On
the other hand, in cases phrased as intrinsic radiosensitivity cases,
there is no sign of radiosensitivity in advance, and it is coded in a com-
plex unknown genetic pattern.
In a multicentre study including 502 breast cancer patients,
86.4% showed late side effects 3 years after radiotherapy, of which
47.8% of patients were grade 1, 13.4% grade 2, and 0.6% grade 3+
fibrosis.8 Others published 6%,9 12.6%,10 and even 23%11 of ≥grade
2 fibrosis. In a study where 47 patients were treated without addi-
tional chemotherapeutic drugs after lumpectomy, 30 patients
showed grade 1, 12 patients grade 2, and 1 patient grade 3 skin
reaction.12 In a study of Hoeller et al, 87 breast cancer patients were
studied to reveal the relationship of chromosome aberrations and
fibrosis. Ten patients developed fibrosis grade 2 or 3 in 1 to 8 years,
and patients with more lethal (≥6.8 dicentric and acentric fragments)
chromosome aberrations showed a higher annual fibrosis rate than
patients with low and intermediate chromosome aberration rates.13
In general, Azria et al stated that in all radiotherapy patients 5%
to 10% of the patients develop severe toxicities, decreasing their
quality of life.14
Differential diagnosis and the management of severe fibrosis is
challenging to physicians, radiologists, radiobiologist, and surgeons.
We report a case of progressive breast fibrosis in a 61‐year‐old
woman treated by 3D conformal breast irradiation, studied by radiobi-
ological methods and treated by reconstructive surgery. Complex care
by cytogenetic investigation combined with reconstructive surgery of
radiotherapy‐treated patients has not been published in the literature
so far.1.1 | Case
A Caucasian female patient (age 61) without any history of cancer was
referred to our institution in August 2014 for a non‐palpable cancer in
her right breast, detected by mammography screening. Core biopsy
proved invasive ductal carcinoma. The Multidisciplinary Tumour Board
indicated radioguided occult lesion localization excision and sentinelnode biopsy (tumour 15 mm, grade III, without LVI, ER 100%, PR
15%, Ki67 17% to 18% Her2neg., negative sentinel lymph node).
After surgery (September 2014), the patient had no complains,
and the cosmetic result was satisfactory. Between November 2014
and January 2015, right sided whole breast irradiation was adminis-
tered by CT‐based, 3D conformal technique with a total dose of 50
Gray (Gy) in 25 daily fractions of 2 Gy, five times a week. The breast
PTV volume was 533 cm3, and the maximum dose was 57.44 Gy. As
acute toxicity, Grade II erythema occurred that was treated with oily
cream. Subcutaneous oedema and pain was not observed. Endocrine
therapy (aromatase inhibitor) was introduced after irradiation. After
8 weeks, the patient had no complaints, and acute skin side effects
disappeared. After 4 months, right breast skin became hyperpig-
mented, and mildly dense tissue in the lower quadrants was palpable.
Two months later (6 months after radiotherapy), this palpable subcuta-
neous abnormality became moderate, and breast pain occurred. Stag-
ing examinations and tumour markers were negative. Seven months
after irradiation, breast MRI was performed due to breast pain: on
the right side, the pectoral major muscle was wider, and concentric
skin thickening was observed, but there was no residual tumour, or
recurrence. Further systematic control examinations were performed;
increased lesion was detected, and the patient complained of pain.
One and a half year after radiotherapy, our patient had the suspicion
of breast tumour recurrence; however, what MRI examination
detected was not tumour but a fibrotic residual gland in the breast
with moderate involution. Short‐TI Inversion Recovery measurement
showed high circular skin thickening due to irradiation. Also, the right
pectoral muscle was wider than its counterpart, a possible post‐thera-
peutic consequence. There was no evidence of abnormal contrast
enhancement or signal intensity, which might have indicated the pres-
ence of tumour tissue. Core‐biopsy revealed extensive fibrosis and fat
necrosis. In the skin excisions of the breast, the dermis were thickened
and scarred; there were some irregular collagen fibre multiplications,
decrease in the number or lack of the skin appendages, and dilated
lymphatic vessels. In the excisions from the side line area, moderate
nodal lymphoplasmocyter infiltration could be seen penetrating the
collagen fibres. Mucus deposition was not identifiable. The deeper
layer of the dermis was oedematously loosened in some places. There
were no signs of malignancy. In October 2016, significant lymph
oedema and pain appeared in the right breast due to progressive fibro-
sis. The skin of the breast became purple at the breast periphery
region and the breast tissue shrunk to a third. However, irradiation‐
caused widening of the pectoral muscle, concentric skin thickening,
and diffuse fibrosis were also observed (Figure 1).
Such severe radiogenic fibrosis is unusual (but not unique), and
since our laboratory performs combined radiosensitivity experiments
in vitro and in clinical studies, we decided to investigate this case.
We also aimed to verify or exclude a potential local over dosage and
reassure the patient that the symptoms were not associated with
tumour recurrence. Therefore, we studied the chromosome aberra-
tions in the lymphocytes of irradiated and non‐irradiated blood after
culture and preparation. Heparinised peripheral blood obtained from
the patient was irradiated for cytogenetic analysis of intrinsic radio-
sensitivity as follows.15 Two millilitre blood was placed in water‐filled
plastic phantom in cryotubes, and radiation field was planned with
FIGURE 1 Severe fibrosis of the patient
18 months after radiotherapy
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with 3 and 6 Gy at 1400 monitor unit/min (MU/min) and 6 MV on a
Varian True‐Beam linear accelerator in flattening filter free mode.16
Lymphocytes do not divide in blood, they should be stimulated with
phytohaemagglutinin and after 48 hours treated with colcemid, a
mitotic (spindle formation) inhibitor. Lymphocytes were suspended in
a hypotonic solution and then fixed with methanol:acetic acid solution
to precipitate both the proteins and DNA in chromosomes. Smears of
cells blocked in metaphase were prepared on glass plates followed by
Giemsa staining and microscopic analysis.17 Two hundred metaphases
on eight plates were analysed; in all metaphases, all aberrations were
counted, and the aberrations of a hundred metaphases were summed.
The standard error of mean was calculated between the groups
consisting of a hundred cells. (Figure 2 shows an aberrant cell of the
patient and a healthy cell of a control individual.) Values of healthy
and cancerous populations whose blood were irradiated under same
conditions (non‐small cell lung cancer patients T1a‐T2a, N0M0) were
matched to our data.
Unirradiated (spontaneous) chromosomal aberration values of the
patient showed 12‐fold (significant) and 2.5‐fold (non‐significant)
increase in the number of dicentric + ring chromosomes, when theyFIGURE 2 Representative pictures of
chromosomes of our patient (A) and of a
healthy control (B)were compared with healthy (N = 5) and cancerous controls (N = 5),
respectively (Figure 3A). The numbers of unirradiated total aberrations
were 2.7‐fold and 13‐fold higher than of healthy and cancerous con-
trol groups, respectively (both differences are significant) (Figure 3B).
Moreover, the patient's samples irradiated with 3 and 6 Gy in vitro
showed more than 1.2‐fold total aberrations and more than 1.7‐fold
dicentric + ring aberrations than any matched controls. The differ-
ences are significant in case of the 3‐Gy irradiation for total aberra-
tions and in case of 3 and 6 Gy for dicentric + ring chromosomes.
These results suggested that our patient had intrinsic radiosensi-
tivity, which caused severe fibrosis in the breast after standard radio-
therapy. Our analysis showed that there was no dosimetric
miscalculation, and it was important to verify, because based on these
results the patient has been advised, that she should not get any fur-
ther radiotherapy or radiation‐based imaging methods (eg, bone or
brain metastases irradiation or CT examinations).
Due to the patient's severe complaints, mastectomy, ablation of
the scabby tissue, and replacing the damaged tissue with one of the
dorsal lobe were recommended by the Multidisciplinary Tumour
Board. Tissues affected by progressive fibrosis were removed, the
inner scars were released, scabby parts of the pectoral muscle were
FIGURE 3 Number of dicentric + ring chromosomes (A) and total aberrations (B) in unirradiated blood and after 3 and 6 Gy in vitro irradiation.
(Data are marked with * if values of our patient are significantly different from both healthy and cancerous control and marked with # if they are
significantly different from healthy control. ANOVA analysis is made in Statistica 7 software with the parameters: CI = 95%, P < 0.05)
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reconstruction. No complications occurred, and the cosmetic result
was satisfactory (Figure 4). On control 2 months after the surgery,
there were no complaints, and the patient was able to raise her arm
above her head, a movement impossible due to fibrosis before
surgery.2 | DISCUSSION
Radiobiology research focused for decades to find promising bio-
markers in severe fibrosis cases which cannot be explained with single
gene deficiences (ATM, XPA). Cytogenetic methods provided positive
predictive value in numerous, but small cohort studies. For example,FIGURE 4 Onco‐plastic surgery with dorsal lobe reconstructionmicronucleus tests were performed on the blood sample of 38 pros-
tate cancer patients taken before radiotherapy which were irradiated
with 1 to 4 Gy. The lymphocytes of the patients who developed more
severe radiogenic toxicities after radiotherapy showed significantly
more micronucleus number than patients' without severe side effects.
This effect was measurable only with more than 2‐Gy irradiation of
the blood samples.18 However, micronucleus method is less sensitive
than chromosome aberration technique.19 In a previously mentioned
study with 47 breast cancer cases using 3‐Gy in vitro irradiation
before therapy, patients with more translocations (proved by FISH
technique) showed less latency period before late skin effects
appeared.12 In a cohort study including 87 cases of breast cancer
patients, it was shown that 6‐Gy but not 3‐Gy irradiation of patients'
blood before radiotherapy induced chromosome aberrations and was
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study, radiation of lymphocytes in G2 phase was not found to be a
good predictor of either acute or late toxicities in 72 larynx tumour
patients.20 The chromosome aberration method is cheap but highly
labour intensive, which could limit its wider use. On the other hand,
it is expected that in the future automatization will be possible, as
there are attempts to achieve this purpose.21,22
It is widely accepted that in most cases no single gene is respon-
sible for radiosensitivity; therefore, research is focused on gene
expression and single polymorphism patterns, but both are highly
expensive. On the other hand, “Radiation‐induced CD8 T‐lymphocyte
Apoptosis” method has negative predictive value and marks patient
population with no radiation toxicity risk.8,23,24 The method uses lym-
phocytes as normal tissue surrogate and has been tested in large clin-
ical cohort and at various tumour sites. This method revealed that the
risk of fibrosis was decreased in non‐smoking population and those
without adjuvant hormone therapy. (Our patient was treated with aro-
matase inhibitor after radiotherapy and was a non‐smoker.)
On the basis of literature data and our experience, we propose
cytogenetical characterisation of cancer patients before their radio-
therapy may identify patients with increased risk of late side effect.
These patients could be treated with mastectomy to avoid irradi-
ation, and oncoplastic reconstruction or with brachytherapy, which
has been shown to cause less toxicity, and might get tamoxifen free
hormone therapy or newer chemotherapy regimens with taxane.11
Cessation of smoking is even more advisable for this group of patients.
Recently, new radiation mitigators and normal tissue radio protectors
are under investigation.25
In the case of potential radiation overexposure accidents, the use
of chromosomal aberration assay is also advisable after radiotherapy,
for example in the case of severe late toxicities. Radiation‐induced
fibrosis occurring more than a decade after breast cancer therapy with
the suspicion of recurrent breast tumour has been reported in the lit-
erature.26 Therefore, patients with the suspicion of tumour recurrence
that has been precluded by biopsy may also benefit because further
ionising load (X‐ray, CT scans) can be reduced.
3 | CONCLUSIONS
Our research has shown that chromosomal aberration technique can
help getting information about the cause of radiogenic progressive
fibrosis and plays a role in the decision of further radiotherapy or
the choice of imaging methods. We propose the use of this methodol-
ogy for the investigation of other radiation toxicities and even before
radiotherapy to detect patients more susceptible for late toxicities.
The most important message of our work is that a multidisciplinary
approach can manage even a complicated case. It is also demonstrated
that reconstructive surgery can solve severe fibrosis cases for the
satisfaction of the patient.4 | ETHICAL STATEMENT
The study was approved by the Local Ethics Committee in strict com-
pliance with the Declaration of Helsinki. Patient's written consent was
obtained for publication of this case report.AUTHORS ' CONTRIBUTIONS
All authors had full access to the data in the study and took responsi-
bility for the integrity of data and accuracy of the data analysis. Con-
ceptualization, N.M. and J.F.; Methodology, G.F; G.S., and P.B.K.;
Investigation, Z.S.K.; Writing—Original Draft, N.M.; Writing—Review &
Editing, Z.J.; Supervision, C.P.
ACKNOWLEDGEMENT
We highly acknowledge the contribution of Dr Zsuzsa Sándor, who
analysed the pathologic samples of our patient. Furthermore, special
thanks for Krisztina Kiss technician for the preparation of the chromo-
some samples.
CONFLICT OF INTEREST
Norbert Meszaros, Gyongyi Farkas, Gabor Szekely, Zsuzsa S. Kocsis,
Peter Bertalan Kelemen, Janos Fodor, Csaba Polgar, and Zsolt Juranyi
state that there are no conflicts of interest.
ORCID
Norbert Mészáros http://orcid.org/0000-0002-1570-7565
REFERENCES
1. Hille‐Betz U, Vaske B, Bremer M, et al. Late radiation side effects, cos-
metic outcomes and pain in breast cancer patients after breast‐
conserving surgery and three‐dimensional conformal radiotherapy:
risk‐modifying factors. Strahlenther Onkol. 2016;192(1):8‐16.
2. Goffman TE, Laronga C, Wilson L, Elkins D. Lymphedema of the arm
and breast in irradiated breast cancer patients: risks in an era of dra-
matically changing axillary surgery. Breast J. 2004;10(5):405‐411.
3. Seam RK, Revannasiddaiah S, Bhardwaj B, Gupta MK. Pulmonary apical
fibrosis in a patient treated earlier for breast cancer. BMJ Case Rep.
2013;2013.
4. Liu LK, Ouyang W, Zhao X, et al. Pathogenesis and prevention of
radiation‐induced myocardial fibrosis. Asian Pac J Cancer Prev. 2017;
18(3):583‐587.
5. Hojan K, Milecki P. Opportunities for rehabilitation of patients with
radiation fibrosis syndrome. Rep Pract Oncol Radiother. 2014;19(1):1‐6.
6. Denham JW, Hauer‐Jensen M. The radiotherapeutic injury—a complex
‘wound’. Radiother Oncol. 2002;63(2):129‐145.
7. Lilla C, Ambrosone CB, Kropp S, et al. Predictive factors for late normal
tissue complications following radiotherapy for breast cancer. Breast
Cancer Res Treat. 2007;106(1):143‐150.
8. Azria D, Riou O, Castan F, et al. Radiation‐induced CD8 T‐lymphocyte
apoptosis as a predictor of breast fibrosis after radiotherapy: results of
the prospective multicenter French trial. EBioMedicine. 2015;2(12):
1965‐1973.
9. Bourgier C, Castan F, Riou O, et al. Impact of adjuvant hormonotherapy
on radiation‐induced breast fibrosis according to the individual radio-
sensitivity: results of a multicenter prospective French trial.
Oncotarget. 2018;9(21):15757‐15765.
10. Collette S, Collette L, BudihartoT, et al. Predictors of the risk of fibrosis
at 10 years after breast conserving therapy for early breast cancer: a
study based on the EORTC trial 22881‐10882 ‘boost versus no boost’.
Eur J Cancer. 2008;44(17):2587‐2599.
11. Johansen J, Overgaard J, Overgaard M. Effect of adjuvant systemic
treatment on cosmetic outcome and late normal‐tissue reactions after
breast conservation. Acta Oncol. 2007;46(4):525‐533.
6 of 6 MÉSZÁROS ET AL.12. Huber R, Braselmann H, Geinitz H, et al. Chromosomal radiosensitivity
and acute radiation side effects after radiotherapy in tumour patients—
a follow‐up study. Radiat Oncol. 2011;6(1):32.
13. Hoeller U, Borgmann K, Bonacker M, et al. Individual radiosensitivity
measured with lymphocytes may be used to predict the risk of fibrosis
after radiotherapy for breast cancer. Radiother Oncol. 2003;69(2):
137‐144.
14. Azria D, Lapierre A, Gourgou S, et al. Data‐based radiation oncology:
design of clinical trials in the toxicity biomarkers era. Front Oncol.
2017;7:83.
15. Borgmann K, Hoeller U, Nowack S, et al. Individual radiosensitivity
measured with lymphocytes may predict the risk of acute reaction
after radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71(1):256‐264.
16. Vassiliev ON, Titt U, Ponisch F, et al. Dosimetric properties of photon
beams from a flattening filter free clinical accelerator. Phys Med Biol.
2006;51(7):1907‐1917.
17. Gundy S, Varga LP. Chromosomal aberrations in healthy persons.
Mutat Res. 1983;120(2–3):187‐191.
18. Lee TK, Allison RR, O'Brien KF, et al. Lymphocyte radiosensitivity cor-
related with pelvic radiotherapy morbidity. Int J Radiat Oncol Biol Phys.
2003;57(1):222‐229.
19. Perumal V, Gnana Sekaran TS, Raavi V, et al. Radiation signature on
exposed cells: relevance in dose estimation. World J Radiol.
2015;7(9):266‐278.
20. Lisowska H, Lankoff A, Wieczorek A, et al. Enhanced chromosomal
radiosensitivity in peripheral blood lymphocytes of larynx cancer
patients. Int J Radiat Oncol Biol Phys. 2006;66(4):1245‐1252.21. Finnon P, Lloyd D. A preliminary evaluation of the Edinburgh dicentric
hunter. J Radiat Res. 1992;33(Suppl):215‐221.
22. Bayley R, Carothers A, Chen X, et al. Radiation dosimetry by automatic
image analysis of dicentric chromosomes. Mutat Res. 1991;253(3):
223‐235.
23. Bordon E, Henriquez‐Hernandez LA, Lara PC, et al. Role of CD4 and
CD8 T‐lymphocytes, B‐lymphocytes and natural killer cells in the pre-
diction of radiation‐induced late toxicity in cervical cancer patients.
Int J Radiat Biol. 2011;87(4):424‐431.
24. Foro P, Algara M, Lozano J, et al. Relationship between radiation‐
induced apoptosis of T lymphocytes and chronic toxicity in patients
with prostate cancer treated by radiation therapy: a prospective study.
Int J Radiat Oncol Biol Phys. 2014;88(5):1057‐1063.
25. Maier P, Wenz F, Herskind C. Radioprotection of normal tissue cells.
Strahlenther Onkol. 2014;190(8):745‐752.
26. Sarsenov D, Aktepe F, Ozmen V. Radiation fibrosis syndrome imitating
breast cancer recurrence; a case report. J Breast Health.
2017;13(1):40‐42.
How to cite this article: Mészáros N, Farkas G, Székely G,
et al. Progressive breast fibrosis caused by extreme radiosensi-
tivity: Oncocytogenetic diagnosis and treatment by recon-
structive flap surgery. Cancer Reports. 2019;2:e1126. https://
doi.org/10.1002/cnr2.1126
